Investment House LLC Sells 3,041 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Investment House LLC decreased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 4.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 65,265 shares of the medical research company's stock after selling 3,041 shares during the period. Investment House LLC owned about 0.13% of Charles River Laboratories International worth $12,048,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Fiduciary Financial Group LLC grew its position in shares of Charles River Laboratories International by 3.9% in the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock valued at $310,000 after purchasing an additional 63 shares in the last quarter. Pinnacle Bancorp Inc. grew its holdings in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares in the last quarter. M&T Bank Corp increased its position in shares of Charles River Laboratories International by 3.4% during the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock valued at $394,000 after buying an additional 66 shares during the period. Cornerstone Investment Partners LLC increased its position in shares of Charles River Laboratories International by 3.7% during the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock valued at $358,000 after buying an additional 69 shares during the period. Finally, Metis Global Partners LLC lifted its holdings in shares of Charles River Laboratories International by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock worth $318,000 after buying an additional 72 shares in the last quarter. Institutional investors own 98.91% of the company's stock.

Remove Ads

Charles River Laboratories International Trading Up 1.2 %

Shares of Charles River Laboratories International stock traded up $1.94 during trading on Friday, reaching $167.29. The company's stock had a trading volume of 1,638,932 shares, compared to its average volume of 725,184. The company has a market cap of $8.55 billion, a price-to-earnings ratio of 1,115.26, a PEG ratio of 4.54 and a beta of 1.45. The firm's 50-day moving average is $166.11 and its two-hundred day moving average is $183.71. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $273.57. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company's revenue was down 1.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.46 earnings per share. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. William Blair cut shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Bank of America reduced their target price on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. Barclays lowered their price target on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 18th. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Finally, UBS Group reaffirmed a "neutral" rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. One research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of "Hold" and a consensus target price of $189.77.

Insider Buying and Selling

In other news, CEO James C. Foster purchased 6,075 shares of the company's stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Birgit Girshick purchased 1,514 shares of the business's stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).